Julien Sarah, Challier Inès, Malleter Marine, Jouen Fabienne, Drouot Laurent, Boyer Olivier
INSERM U1234, PAn'THER FOCIS Center of Excellence, Université de Rouen, F-76000 Rouen, France.
Department of Pharmacy, CHU Rouen, F-76000 Rouen, France.
Antibodies (Basel). 2024 Feb 7;13(1):12. doi: 10.3390/antib13010012.
Immune-mediated necrotizing myopathy (IMNM) is a rare and severe disease that corresponds to a specific entity of idiopathic inflammatory myopathy. Patients with IMNM suffer from proximal muscle weakness, and present high levels of creatine kinase and necrotic myofibers. Anti-Signal Recognition Particle (SRP) and anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase autoantibodies (HMGCR) have recently been identified in two thirds of patients with IMNM and are used as a hallmark of the disease. In this review, we provide a detailed description of these antibodies and the tests used to detect them in the serum of patients. Based on in vitro studies and mouse models of IMNM, we discuss the role of autoantibodies in the pathogenesis of the disease. Finally, in the light of the latest knowledge, we conclude with a review of recent therapeutic approaches in IMNM.
免疫介导性坏死性肌病(IMNM)是一种罕见且严重的疾病,属于特发性炎性肌病的一个特定类型。IMNM患者存在近端肌无力,肌酸激酶水平升高且有坏死性肌纤维。近期在三分之二的IMNM患者中发现了抗信号识别颗粒(SRP)和抗3-羟基-3-甲基戊二酰辅酶A还原酶自身抗体(HMGCR),它们被用作该疾病的标志。在本综述中,我们详细描述了这些抗体以及用于检测患者血清中这些抗体的检测方法。基于IMNM的体外研究和小鼠模型,我们讨论了自身抗体在该疾病发病机制中的作用。最后,根据最新知识,我们对IMNM最近的治疗方法进行了综述。